ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2020

Dec 11, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2020-12-08

Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-08	Common Stock	M	16324	$2.01	Acquired	2521561	Direct
2020-12-08	Common Stock	S	16324	$67.97	Disposed	2505237	Direct
2020-12-09	Common Stock	M	38676	$2.01	Acquired	2543913	Direct
2020-12-09	Common Stock	S	16726	$67.27	Disposed	2527187	Direct
2020-12-09	Common Stock	S	12067	$69.80	Disposed	2515120	Direct
2020-12-09	Common Stock	S	5880	$70.87	Disposed	2509240	Direct
2020-12-09	Common Stock	S	4003	$71.61	Disposed	2505237	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-08	Stock Option (right to buy)	$2.01	M	16324	Disposed	2023-05-06	Common Stock (16324)	Direct
2020-12-09	Stock Option (right to buy)	$2.01	M	38676	Disposed	2023-05-06	Common Stock (38676)	Direct

Footnotes

F1: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.50 to
$68.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead
Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares
sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.26 to $69.26, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F3: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.27 to $70.25, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.32 to $71.30, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F5: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.33 to $72.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F6: Includes a total of 900,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance
goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole.

F7: Represents first vesting date. Option vested over four years from date of grant.